ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at two upcoming conferences in Boston, MA this fall. Both conferences are invitation only for presenting companies, and showcase leading drug development organizations working to advance groundbreaking new therapies. The first, Outsourcing in Clinical Trials, will be held on September 16-17, 2015. Conference location and agenda information are available at their website. The second conference, Discovery on Target, will be held on September 22-24. Additional information can be found on the conference website. Andarix’ CEO will present Tozaride, the company’s lead development candidate and give an update on clinical development in orphan drug indications. Mr. Adams will be available for meetings at the conference.
Tozaride is a novel, best-in-class therapy for lung and other cancers based on a proprietary radio-labeled somatostatin peptide. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in heavily pre-treated advanced lung cancer patients. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) patients, and provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s clinical stage development candidates are based on its proprietary somatostatin peptide conjugate. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung, pancreatic and neuroendocrine cancers. To learn more about Andarix, please visit www.andarix.com.